Clinical Trials

Multiple Sclerosis Research:

PASSAGE – Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

This study is for patients with relapsing forms of MS, who are newly starting treatment with Gilenya (fingolimod) at the beginning of their trial participation. Participants are only asked to attend their normal office visits, from which anonymous medical information is taken to contribute to an ongoing safety analysis of this medication. Enrolled patients will have our office visits paid for by the study until 2022, but don’t wait, enrollment ends soon!

Learn more about PASSAGE

Neurogenic Orthostatic Hypotension (NOH) Research:

RESTORE – Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension

The purpose of this study is to evaluate the efficacy and safety of Northera (droxidopa) to treat neurogenic orthostatic hypotension (NOH). NOH symptoms include dizziness, lightheadedness, or feelings that you may black out upon standing. This medication is for patients who also have Parkinson’s Disease (PD), Multiple System Atrophy (MSA), Pure Autonomic Failure (PAF), Non-Diabetic Autonomic Neuropathy (NDAN) or Dopamine Beta-Hydroxylase (DBH) deficiency. Northera has been approved by the FDA, and participants will receive medication and office appointments paid for during the study, as well as compensation for participation and travel expenses!

Learn More about RESTORE


To learn more about participating in one of these studies, please contact our Clinical Research Site Director and Study Coordinator:

Tanya Alexander, CRC

Tanyaa@integratedneurologyservices.com
703-313-9111 ext. 107

Ms. Alexander has over 30 years’ experience in Phase I, II, III & IV trials.  She started her career as a Research Assistant.  She worked as a Study Coordinator in the private sector and university.  She has also worked in the Contract Research Organization industry as a contract and budget coordinator.

 


Study sponsors: Our office is interested in further expansion and diversification of our clinical trials so that we can offer these opportunities to more of our patients. If you are currently recruiting sites for any clinical trial pertaining to a neurological condition that does not compete with our current trials, feel free to call or email Tanya with information!